ST 1535

ST 1535 is a potent and orally active A2A adenosine receptor antagonist. ST 1535 shows antiparkinsonian activity and antitremorigenic effects. ST 1535 has the potential for the research of Parkinson’s disease[1][2].

Product Specifications

CAS Number

[496955-42-1]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Adenosine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/st-1535.html

Purity

99.80

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

CN1C(N2N=CC=N2)=NC3=C1N=C(CCCC)N=C3N

Molecular Formula

C12H16N8

Molecular Weight

272.31

Precautions

H302, H315, H319, H335

References & Citations

[1]Stasi MA, et al. ST 1535: a preferential A2A adenosine receptor antagonist. Int J Neuropsychopharmacol. 2006 Oct;9 (5) :575-84.|[2]Tronci E, et al. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. Eur J Pharmacol. 2007 Jul 2;566 (1-3) :94-102.